Accession Number:



Fusion Genes Predict Prostate Cancer Recurrence

Descriptive Note:

Technical Report,15 Sep 2017,14 Sep 2018

Corporate Author:

Leland Stanford Junior University Stanford United States

Personal Author(s):

Report Date:


Pagination or Media Count:



Most prostate are indolent, and may not require clinical intervention. Only a small fraction of cases progress to metastatic disease if not treated. Prediction of the clinical outcomes of prostate cancer remains a challenge. Recently, we discovered a panel of 8 fusion genes that occurred in aggressive prostate cancer. The presence of these fusion genes correlates 91 chance of recurrence of prostate cancer. In order to make the fusion gene test clinically ready as a predictor, we have modified to test into a semi-quantitative Taqman QRT-PCR. The tests were performed in CLIA certified lab. Four hundred and sixty samples of prostate cancers were collected. Prostate cancer cells were microdissected. Taqman QRT-PCRs were performed on these samples. Significant numbers of samples were found positive for some of these fusion genes. In addition, we have analyzed 150 samples from Stanford University and 155 samples from University of Wisconsin Madison. A training model has been constructed. We are in the process to apply the model to testing sets.

Subject Categories:

  • Medicine and Medical Research
  • Genetic Engineering and Molecular Biology
  • Biochemistry

Distribution Statement: